GDF-8 (Myostatin) Research Guide — ActRIIB/ALK4–5/Smad2–3 Signaling Mechanism & Muscle Atrophy Research Applications (2026)
- GDF-8 (growth differentiation factor-8; myostatin; MSTN) is an endogenous TGF-β superfamily protein first identified by McPherron et al. (1997, Nature, PMID: 9139826) as a muscle-specific negative regulator of skeletal muscle mass. Mice with targeted myostatin gene deletion display a dramatic hypermuscular phenotype; inactivating mutations have been identified in Belgian Blue and Piedmontese cattle (“double muscled”) and in one documented hypermuscular human child. As a research compound, recombinant GDF-8 is used to induce the myostatin signaling state in cell culture and in vitro muscle models, activating the canonical ActRIIB/Smad2–3 pathway that suppresses muscle protein synthesis and satellite cell function. YPB offers research-grade recombinant GDF-8 as YPB.233 (Research Use Only).
- Mechanism: Mature GDF-8 (a disulfide-linked homodimer) binds ActRIIB (activin receptor type IIB) with high affinity. The bound ActRIIB then recruits the type I serine/threonine kinase co-receptor ALK4 (most commonly) or ALK5 to form a heteromeric receptor complex. ActRIIB transphosphorylates ALK4/5, which in turn phosphorylates Smad2 and Smad3. Phospho-Smad2/3 form a complex with Smad4 and translocate to the nucleus, where they: (1) suppress MyoD and myogenic differentiation gene expression → inhibit satellite cell activation and myoblast differentiation; (2) inhibit IGF-1/Akt/mTOR signaling → reduce muscle protein synthesis; and (3) activate FoxO transcription factors → upregulate MuRF1 and MAFbx ubiquitin E3 ligases → increase muscle protein degradation. The cumulative result is the canonical “muscle brake” signaling state.
- Research utility: Recombinant GDF-8 is the pharmacological agonist for the myostatin/ActRIIB pathway, used to induce muscle atrophy/inhibition states for mechanistic studies, to validate the specificity of ActRIIB pathway inhibitors (paired with ACE-031), and to study myostatin signaling in sarcopenia, DMD, cachexia, and obesity-related muscle dysfunction models. It is the direct pharmacological complement to ACE-031: GDF-8 activates the pathway; ACE-031 blocks it.
- Important note: GDF-8 shares ~90% amino acid sequence identity with GDF-11 in the mature domain. This cross-reactivity means that some anti-GDF-8 antibodies also bind GDF-11, and some GDF-8 research findings may involve GDF-11 co-activation. Research protocols requiring GDF-8-specific vs. GDF-11-specific effects need appropriate controls. YPB.233. Research Use Only (RUO). Updated April 2026.
What Is GDF-8 (Myostatin) and Why Is It Central to Muscle Biology Research?
Endogenous Muscle Mass Negative Regulator
ActRIIB/Smad2–3 Pharmacological Probe
GDF-8, formally designated growth differentiation factor-8 and commonly known as myostatin, is the primary endogenous brake on skeletal muscle mass accumulation. Updated April 2026. Its discovery by McPherron, Lawler, and Lee in 1997 (Nature 387:83–90; PMID: 9139826) was one of the most significant findings in muscle biology of the 20th century: GDF-8 knockout mice displayed dramatically increased muscle mass (“double the muscle” compared to wild-type), establishing that a single secreted protein maintains the physiological upper limit on how much skeletal muscle can accumulate. The practical implication was immediately recognized: pharmacological inhibition of GDF-8/myostatin was a viable target for treating muscle wasting diseases including muscular dystrophy, sarcopenia, and cancer cachexia.
As a research compound, recombinant GDF-8 serves the complementary role to the inhibitors that followed its discovery: it is the agonist probe for the myostatin signaling pathway, used to activate ActRIIB/Smad2–3 signaling in cell culture and in vivo models, to validate inhibitor specificity, and to study the molecular mechanisms by which muscle mass is actively suppressed. The GDF-8 + ACE-031 pair (agonist + antagonist for the same pathway) is the most mechanistically complete ActRIIB research toolkit available.
Key Characteristics
| Parameter | Value |
|---|---|
| Full Name | Growth differentiation factor-8; myostatin; MSTN; GDF-8 |
| Discovery | McPherron, Lawler, Lee (1997) Nature 387:83–90. PMID: 9139826. Identified by degenerate PCR as muscle-specific TGF-β family member. |
| Classification | TGF-β superfamily member; secreted signaling protein; expressed predominantly in skeletal muscle; minor expression in heart, adipose |
| YPB SKU | YPB.233 |
| Active Form | Disulfide-linked homodimer of the mature C-terminal domain (~26 kDa per monomer; ~52 kDa dimer). Processed from a larger precursor (pro-GDF-8) by furin-like protease; propeptide remains non-covalently associated forming a latent complex; BMP-1/tolloid proteases release active mature dimer. |
| Receptor Complex | ActRIIB (type II serine/threonine kinase receptor; high affinity primary binding) → recruits ALK4 or ALK5 (type I co-receptor) → heteromeric receptor complex |
| Downstream Signaling | ActRIIB transphosphorylates ALK4/5 → ALK4/5 phosphorylates Smad2 and Smad3 → phospho-Smad2/3 + Smad4 → nuclear translocation → MyoD suppression + IGF-1/Akt inhibition + FoxO activation + MuRF1/MAFbx upregulation |
| Net Physiological Effect | Suppresses satellite cell activation and myoblast differentiation; reduces muscle protein synthesis (mTOR inhibition); increases muscle protein degradation (ubiquitin-proteasome via MuRF1/MAFbx); maintains muscle mass within physiological bounds |
| Loss-of-Function Phenotype | GDF-8 KO mice: hypermuscular (double the muscle mass). Belgian Blue/Piedmontese cattle: natural MSTN null mutations → double-muscled phenotype. One documented hypermuscular human child (natural inactivating mutation). |
| GDF-11 Cross-Reactivity | ~90% mature domain sequence identity with GDF-11; many anti-GDF-8 antibodies cross-react with GDF-11; research protocols requiring GDF-8-specific effects need validated anti-GDF-8 tools with confirmed GDF-11 selectivity |
| Half-Life (endogenous) | Endogenous GDF-8 circulates predominantly in the latent propeptide-bound form; free active GDF-8 has short half-life; recombinant mature GDF-8 added to culture medium is active within minutes of receptor contact |
| FDA Status | Endogenous human protein; recombinant form is a research reagent only. Not research-grade for any human use. Research Use Only (RUO). |
| WADA Status | Not listed on WADA Prohibited List 2025 (endogenous protein; research reagent use only) |
| Storage | Lyophilized: −20°C. Reconstituted in 0.1% BSA/PBS; 2–8°C, use within 7 days. Mature GDF-8 dimer is susceptible to aggregation at high concentration and with repeated freeze-thaw; aliquot single-use portions. |
How Does GDF-8 Signal? The ActRIIB/ALK4–5/Smad2–3 Cascade
Propeptide Processing and Activation
GDF-8 is synthesized as a larger prepro-protein. The signal peptide is cleaved co-translationally; the resulting pro-GDF-8 then undergoes two rounds of proteolytic processing. First, furin-like proprotein convertases cleave at a dibasic site to separate the N-terminal prodomain (propeptide) from the C-terminal mature growth factor domain. Second, the mature GDF-8 dimer forms via disulfide bonds and assembles into a latent complex with the propeptide through non-covalent interactions — the propeptide acts as an endogenous inhibitor that keeps GDF-8 in a latent, inactive state in the extracellular space. BMP-1/tolloid metalloproteinases cleave the propeptide at a specific site, releasing the active mature GDF-8 dimer that can then bind ActRIIB. This activation step is a regulated checkpoint: the latent:active ratio of GDF-8 is controlled by tolloid activity, follistatin (an endogenous GDF-8 inhibitor), and GASP-1/GASP-2 (other endogenous inhibitors). For research use, recombinant mature GDF-8 bypasses this propeptide system and directly activates the receptor pathway.
ActRIIB Binding and Heteromeric Complex Formation
Active mature GDF-8 (a cystine-knot homodimer) binds ActRIIB with high affinity via its “wrist” epitope. This binding induces ActRIIB to recruit the type I co-receptor, either ALK4 or ALK5. The resulting heteromeric ternary complex (GDF-8–ActRIIB–ALK4/5) positions the constitutively active ActRIIB kinase domain to transphosphorylate the ALK4/5 GS-domain serine residues, activating ALK4/5 kinase activity. Active ALK4/5 then phosphorylates the C-terminal SSXS motif of receptor-Smads (R-Smads) Smad2 and Smad3.
Nuclear Smad2/3 Signaling → Muscle Atrophy Program
Phospho-Smad2 and phospho-Smad3 form a trimeric complex with the common mediator Smad4 and translocate to the nucleus. Nuclear Smad2/3/4 complexes regulate transcription of genes that collectively drive the muscle atrophy program: (1) suppression of MyoD and myogenin expression, blocking satellite cell activation and myoblast-to-myotube differentiation — the basis of GDF-8’s anti-regenerative effect; (2) antagonism of the IGF-1/PI3K/Akt/mTOR pathway that drives muscle protein synthesis, reducing translational capacity; (3) activation of FoxO transcription factors (FoxO1, FoxO3), which drive expression of the E3 ubiquitin ligases MuRF1 (TRIM63) and MAFbx (atrogin-1/FBXO32) — the primary drivers of muscle protein ubiquitination and proteasomal degradation.
What Research Applications Is GDF-8 Used For?
Muscle Atrophy Induction and Pathway Activation
The primary research application of recombinant GDF-8 is activating the myostatin/ActRIIB/Smad2–3 signaling pathway in cell culture models to: (1) induce the gene expression changes associated with muscle atrophy (MuRF1, MAFbx upregulation; MyoD, myogenin downregulation; mTOR pathway inhibition); (2) inhibit myoblast differentiation and satellite cell fusion in primary or C2C12 cell culture differentiation assays; (3) establish the “myostatin signaling active” baseline for inhibitor validation experiments. GDF-8 is added at 10–100 ng/mL to serum-containing culture medium; Smad2 phosphorylation (detectable within 30–60 minutes) is the canonical rapid-response endpoint for confirming receptor engagement.
Inhibitor Validation (Paired with ACE-031)
The pharmacologically complete ActRIIB research design uses both GDF-8 and ACE-031 in the same study: GDF-8 establishes the signaling-active atrophy baseline; ACE-031 (or other ActRIIB pathway inhibitors) is then used to rescue or prevent the GDF-8-induced signaling and functional atrophy phenotype. This agonist-rescue design is the most rigorous way to confirm that an ActRIIB inhibitor’s observed effects are specifically due to myostatin/activin pathway blockade rather than off-target biology. See the ACE-031 Research Guide for the inhibitor side of this research pair.
Sarcopenia and Aging Muscle Research
GDF-8 expression increases with age and is elevated in sarcopenic muscle, making myostatin signaling a candidate mechanism for age-related muscle loss. Recombinant GDF-8 is used in aged primary satellite cell culture systems to study whether elevated myostatin is the proximal cause of impaired satellite cell activation and myogenesis in aged muscle, or whether it is a downstream marker of other age-related changes.
Cachexia and Disease Atrophy Models
GDF-8 is elevated in cancer cachexia, corticosteroid-induced atrophy, AIDS wasting, and disuse atrophy models. Recombinant GDF-8 is used to establish the myostatin-driven component of these atrophy states in cell culture and organ bath preparations, separating the myostatin contribution from other pro-atrophic pathways (inflammatory cytokines, glucocorticoids, androgen deprivation) that may operate in parallel.
What Does the Research Data Show?
| Evidence Type | Model / Design | Key Finding & Notes | Year |
|---|---|---|---|
| McPherron et al. — Foundational knockout | Genetic (GDF-8 knockout mice) | GDF-8-null mice exhibited dramatic skeletal muscle hypertrophy (approximately double the muscle mass of wild-type); individual muscle masses 2–3-fold greater. Established GDF-8 as the primary endogenous negative regulator of muscle mass. (Nature, 1997, PMID: 9139826) | 1997 |
| Natural loss-of-function models | Livestock (Belgian Blue, Piedmontese cattle) and human case report | Double-muscled cattle breeds have natural MSTN inactivating mutations; demonstrate that chronic myostatin pathway loss produces marked muscle hypertrophy without apparent adverse effects in some species. One documented human child with GDF-8 loss-of-function mutation showed extraordinary muscle development. Confirmed physiological relevance. | 1997–2004 |
| Receptor signaling characterization | In vitro / receptor binding and signal transduction assays | Smad2/3 phosphorylation confirmed as primary intracellular mediator; ALK4/5 type I co-receptor dependency established; IGF-1/Akt signaling antagonism documented; MyoD/myogenin suppression in satellite cell and myoblast models confirmed. PMID literature extensive (multiple groups, 1997–present). | Multiple |
| GDF-8 elevation in disease atrophy | Human tissue and serum; animal models | GDF-8/myostatin levels elevated in sarcopenia, DMD, ALS, HIV wasting, cardiac cachexia, and corticosteroid-induced muscle loss. Correlational data; GDF-8 as potential atrophy biomarker and mechanistic driver in disease contexts. No serious adverse events from recombinant GDF-8 use in cell culture models. | Various |
How Does GDF-8 Compare to Other Muscle Biology Research Compounds?
| Parameter | GDF-8 (Myostatin) | ACE-031 | BPC-157 | IGF-1 LR3 |
|---|---|---|---|---|
| Pathway Role | Endogenous ActRIIB agonist: activates Smad2/3 → muscle suppression | Pan-ActRIIB ligand trap: blocks GDF-8 + activin A/B + GDF-11 → releases muscle suppression | Tissue repair peptide; VEGF/EGF upregulation; angiogenesis; distinct from ActRIIB axis | Downstream GH axis: IGF-1R RTK → PI3K/Akt/mTOR → muscle protein synthesis; opposes GDF-8’s mTOR inhibition |
| Research Function | Pathway AGONIST: induces muscle atrophy state; establishes Smad2/3 signaling baseline; validates inhibitor rescue | Pathway ANTAGONIST: blocks myostatin/activin signaling; best used in agonist-rescue pair with GDF-8 | Repair/angiogenesis tool; orthogonal to myostatin axis | Pro-anabolic: drives protein synthesis via IGFBP-resistant IGF-1R activation; physiological counter to myostatin signaling |
| GDF-11 Cross-reactivity | ~90% mature domain identity with GDF-11; validate recombinant identity by N-terminal sequencing or MS | Traps GDF-11 in addition to GDF-8; pan-ActRIIB effect includes both ligands | No relationship to GDF system | No relationship to GDF system |
| Endpoint in Muscle Research | Smad2/3 phosphorylation (30–60 min); MyoD/myogenin suppression; MuRF1/MAFbx upregulation; inhibited myotube formation; reduced fusion index | Restoration of Smad2/3 baseline; increased myotube mass; fiber hypertrophy; lean mass increase | Vessel density; wound closure rate; growth factor expression | Akt/mTOR phosphorylation; protein synthesis rate; satellite cell proliferation |
| YPB SKU | YPB.233 — see product | YPB.249 — see guide | YPB.201 — see guide | YPB.262 — see guide |
GDF-8 and ACE-031 are the complementary pharmacological pair for ActRIIB pathway research: GDF-8 activates the pathway; ACE-031 (see the ACE-031 Research Guide) inhibits it. IGF-1 LR3 (see the IGF-1 LR3 Research Guide) operates on the pro-anabolic side of the same muscle mass regulation equation: GDF-8 suppresses the IGF-1/Akt/mTOR axis; IGF-1 LR3 directly activates it. Running GDF-8 and IGF-1 LR3 in opposing directions in the same model provides a complete picture of both the anabolic and catabolic arms of muscle mass regulation.
What Should Researchers Know About GDF-8 Handling?
Recombinant GDF-8 vs. Propeptide-Bound Form
Research-grade recombinant GDF-8 is the active mature domain dimer, not the propeptide-bound latent complex. This is important: the recombinant active form bypasses the endogenous tolloid-mediated activation step and is immediately receptor-competent. Researchers studying the regulatory steps upstream of active GDF-8 (propeptide processing, tolloid activity, follistatin inhibition) should use appropriate propeptide-bound latent GDF-8 forms available separately. For Smad2/3 pathway activation studies, the active recombinant dimer is the appropriate form.
GDF-11 Identity Verification
Given the ~90% mature domain sequence identity between GDF-8 and GDF-11, COA verification for recombinant GDF-8 should include N-terminal amino acid sequencing or intact mass spectrometry that can unambiguously distinguish the two proteins at the primary sequence level. HPLC purity alone does not confirm GDF-8 vs. GDF-11 identity. All YPB GDF-8 batches include lot-traceable COA documentation through the COA Library.
Storage and Aggregation Prevention
Lyophilized GDF-8: −20°C for up to 24 months. Reconstitute in sterile 0.1% BSA/PBS or 4 mM HCl; avoid water alone (aggregation risk). Working concentrations: 10–100 ng/mL for Smad2/3 activation in myoblast culture. Prepare single-use aliquots from reconstituted stock to minimize freeze-thaw degradation. Mature GDF-8 dimer can aggregate at >1 µg/mL in carrier-free solutions; BSA carrier improves stability.
Key Research Findings
- McPherron et al. (1997) Nature (PMID: 9139826): GDF-8 knockout mice = hypermuscular (doubled muscle mass); foundational proof that single secreted protein maintains physiological muscle mass upper limit.
- Receptor complex: ActRIIB → ALK4/5 → Smad2/3: Precise cascade from ligand binding to nuclear atrophy program. Smad2 phosphorylation at 30–60 minutes is the canonical rapid-response assay endpoint.
- Three Smad2/3 downstream arms: (1) MyoD/myogenin suppression (anti-differentiation); (2) IGF-1/Akt/mTOR inhibition (anti-protein synthesis); (3) FoxO activation → MuRF1/MAFbx ubiquitin ligases (pro-degradation). Each arm independently measurable by standard assays.
- Natural loss-of-function precedent: Belgian Blue/Piedmontese double-muscled cattle; one human case. Demonstrates that chronic complete myostatin loss in some organisms produces extreme muscle hypertrophy; context for therapeutic inhibitor research.
- ~90% GDF-11 sequence identity: Critical cross-reactivity consideration; N-terminal sequencing or MS required for recombinant identity confirmation; antibody-based inhibition controls need GDF-11 selectivity validation.
- GDF-8 + ACE-031 = canonical inhibitor-rescue design: GDF-8 establishes pathway-active baseline; ACE-031 rescue validates inhibitor specificity for ActRIIB pathway blockade.
- GDF-8 elevated in muscle wasting diseases: Sarcopenia, DMD, cancer cachexia, HIV wasting, corticosteroid atrophy — contextualizes GDF-8 research within multiple disease models.
- Recombinant active dimer bypasses propeptide regulation: For receptor signaling studies; use propeptide-bound latent form for studies of activation step regulation (tolloid, follistatin, GASP-1/2).
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | GDF-8 Data Point |
|---|---|
| PubMed publications | 8,000+ (myostatin / GDF-8 / MSTN) |
| Foundational significance | McPherron 1997 Nature (PMID: 9139826) = one of the most-cited muscle biology papers of the 20th century; launched the entire myostatin inhibitor compound development field |
| Unique catalog position | Only ActRIIB pathway agonist in YPB catalog; paired with ACE-031 creates complete agonist/antagonist toolkit for myostatin pathway research |
| Disease relevance | Sarcopenia; DMD; cancer cachexia; AIDS wasting; corticosteroid atrophy; obesity-related muscle dysfunction — all active funded research areas |
| compound development context | GDF-8 remains one of the most extensively targeted pathways in muscle wasting compound development (next-generation inhibitors: KER-065, apitegromab, trevogrumab, luspatercept) |
| Keyword difficulty range | Low-medium (KD <20); well-established research audience |
How Can Researchers Offer GDF-8 Under Their Own Brand?
Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.233 (RUO) | GDF-8 (Myostatin; recombinant mature dimer) | TBC Premier | TBC Core | TBC | TBC at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering GDF-8 (YPB.233) alongside ACE-031 (YPB.249) create the only complete ActRIIB pathway agonist/antagonist research toolkit in a white-label research catalog — enabling the inhibitor-rescue experimental design that is the gold standard for confirming ActRIIB pathway-specific effects. Adding IGF-1 LR3 adds the pro-anabolic counter-axis: three tools covering both directions of the muscle mass regulation equation. Download the full catalog for all muscle biology category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “GDF-8,” “myostatin,” “MSTN muscle,” “ActRIIB Smad2 Smad3,” and “myostatin knockout skeletal muscle.” Search conducted through April 2026.
Key sources: McPherron et al. (1997) Nature 387:83–90 (PMID: 9139826; foundational discovery); Rebbapragada et al. (2003) PMC230332 (ActRIIB/ALK4/5/Smad2/3 signaling pathway characterization); ScienceDirect myostatin overview (ActRIIB/ALK4/5/FoxO/MuRF1 downstream cascade); PMC11842502 (comprehensive 2025 review of myostatin inhibitor therapeutic landscape including GDF-11 cross-reactivity context).
Limitations: Recombinant mature GDF-8 activates the Smad2/3 pathway directly; results may not fully recapitulate the regulated activation that occurs via propeptide processing and tolloid-mediated release in vivo. ~90% mature domain identity with GDF-11 requires rigorous identity validation for any research claiming GDF-8-specific effects. This article is for educational purposes only.
References
- McPherron, A. C., Lawler, A. M., & Lee, S. J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387(6628), 83–90. PMID: 9139826
- Rebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J., & Bhatt, L. (2003). Myostatin signals through a transforming growth factor β-like signaling pathway to block adipogenesis. Mol Cell Biol, 23(20), 7230–7242. PMC230332 (ActRIIB/ALK4/ALK5/Smad2/3 characterization.)
- Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., Fries, R., Hanset, R., & Georges, M. (1997). A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet, 17(1), 71–74. (Belgian Blue natural MSTN mutation.)
- Schuelke, M., Wagner, K. R., Stolz, L. E., Höhne, W., Zehnder, K., Witt, T., Wieacker, P., & Müller, S. B. (2004). Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med, 350(26), 2682–2688. (Human myostatin loss-of-function case.)
- Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009). Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol, 296(6), C1248–C1257. (Smad2/3 muscle atrophy program.)
- Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., Stantzou, A., Mouisel, E., Toniolo, L., Ferry, A., Stricker, S., Goldberg, A. L., Dupont, S., Piccolo, S., Amthor, H., & Sandri, M. (2013). BMP signaling controls muscle mass. Nat Genet, 45(11), 1309–1318.
- Lee, S. J., & McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA, 98(16), 9306–9311.
- Rodgers, B. D., & Garikipati, D. K. (2008). Clinical, agricultural, and evolutionary biology of myostatin: a comparative review. Endocr Rev, 29(5), 513–534.
- Sartori, R., Romanello, V., & Sandri, M. (2021). Mechanisms of muscle atrophy and hypertrophy: implications in health and disease. Nat Commun, 12(1), 330. (Comprehensive MuRF1/MAFbx/FoxO/mTOR context.)
Frequently Asked Questions
GDF-8 (growth differentiation factor-8; myostatin; MSTN; YPB.233) is an endogenous TGF-β superfamily member first characterized by McPherron et al. (1997, Nature, PMID: 9139826) as the primary negative regulator of skeletal muscle mass. In research models, recombinant mature GDF-8 (active disulfide-linked homodimer) activates ActRIIB (type II serine/threonine kinase receptor) → recruits ALK4/5 co-receptor → heteromeric complex transphosphorylates → Smad2/3 phosphorylation → nuclear Smad2/3/4 complex drives muscle atrophy gene program: (1) MyoD/myogenin suppression → inhibits satellite cell activation and myoblast differentiation; (2) IGF-1/PI3K/Akt/mTOR antagonism → reduces protein synthesis; (3) FoxO activation → MuRF1/MAFbx E3 ligase upregulation → ubiquitin-proteasome degradation. Canonical rapid assay: phospho-Smad2 at 30–60 min. Used as pharmacological agonist for ActRIIB pathway; paired with ACE-031 as inhibitor for agonist-rescue inhibitor validation designs. Not for research use only. Research Use Only (RUO). Updated April 2026.
GDF-8 knockout mice exhibit approximately double the muscle mass of wild-type littermates because GDF-8/myostatin is the constitutive endogenous brake on muscle mass accumulation. In normal animals, GDF-8 is continuously secreted by skeletal muscle fibers and satellite cells throughout life, continuously activating ActRIIB/Smad2/3 signaling that suppresses satellite cell activation, inhibits myoblast proliferation and differentiation, reduces protein synthesis rates, and increases protein degradation. This constitutive suppression keeps muscle mass within physiological bounds despite a continuous anabolic drive from IGF-1, testosterone, and mechanical loading. When GDF-8 is genetically deleted, this brake is released: satellite cells are no longer suppressed, myoblast fusion is enhanced, protein synthesis rates increase, and degradation decreases. Over time, this compound disinhibition results in muscle masses 2–3 times greater than wild-type for individual muscles. The phenotype is dramatically visible — GDF-8 KO mice have visibly bulging muscles that were immediately apparent in the original McPherron 1997 photographs — and demonstrated convincingly that pharmacological inhibition of GDF-8 was a viable strategy for increasing muscle mass in therapeutic contexts.
GDF-8 (myostatin) and GDF-11 share approximately 90% amino acid sequence identity in their mature domains — the highest sequence identity of any two members of the TGF-β superfamily. This near-identity creates three types of cross-reactivity that affect research design. First, many commercial anti-GDF-8 antibodies (both neutralizing and detection antibodies) also bind GDF-11; unless the antibody has been validated by titration against both purified recombinant proteins, “anti-myostatin” results may reflect GDF-11 effects as well. Second, recombinant GDF-8 protein preparations that have not been validated by N-terminal sequencing or intact mass MS may be contaminated with or misidentified as GDF-11 — the commercial anti-doping study issue with GDF-8 adjacent products is relevant context. Third, the biological controversy around GDF-11 as a “youth factor” (Loffredo et al. 2013 Cell; Egerman et al. 2015 Cell Metab rebuttal) was partly fueled by cross-reactive assays that could not clearly distinguish elevated GDF-8 (pro-atrophic) from GDF-11 in aged serum. For rigorous GDF-8-specific research: (1) validate recombinant GDF-8 identity by N-terminal sequencing; (2) use anti-GDF-8 antibodies validated for <5% GDF-11 cross-reactivity; (3) include GDF-11 controls in inhibition experiments to confirm specificity.
The canonical in vitro GDF-8 pathway activation assay uses C2C12 myoblasts or primary satellite cells. Standard protocol: (1) Cells at 70–80% confluence in growth medium (DMEM + 10% FBS); (2) serum-starve for 4–6 hours to reduce baseline Smad2/3 phosphorylation (serum contains growth factors that can activate Smad pathways); (3) add recombinant GDF-8 at 10–100 ng/mL directly to culture medium; (4) incubate at 37°C for 30–60 minutes for acute phospho-Smad2/3 Western blot endpoint, or 24–72 hours for gene expression endpoints (MuRF1, MAFbx, MyoD, myogenin). Positive control: recombinant TGF-β1 (10 ng/mL) activates the same Smad2/3 pathway through TGF-βRI/II. Negative control: include an anti-GDF-8/myostatin neutralizing antibody at excess molar ratio or SB431542 (ALK4/5 inhibitor; direct downstream receptor inhibitor) to confirm GDF-8-specific vs. background phospho-Smad2/3. For inhibitor rescue design: pre-incubate with ACE-031 (30–120 minutes) before GDF-8 addition; confirmed rescue of phospho-Smad2/3 by ACE-031 validates ACE-031’s on-target mechanism.
GDF-8/myostatin is implicated in sarcopenia (age-related muscle loss) through several documented mechanisms. First, myostatin expression and serum myostatin levels are elevated in aged subjects and in sarcopenic muscle vs. young muscle in published studies. Second, aged satellite cells show elevated Smad2/3 phosphorylation and reduced responsiveness to activation stimuli, consistent with chronic myostatin signaling suppression of the satellite cell pool. Third, the satellite cell number declines with age partially due to impaired self-renewal driven by elevated Smad3 signaling (Smad3-null mice show reduced satellite cell number and pronounced sarcopenia, not increased muscle mass — illustrating that Smad3 has both positive and negative roles in muscle homeostasis at different concentrations). Fourth, in animal aging models, myostatin inhibition (using antibodies or soluble ActRIIB) has been shown to preserve or increase muscle mass in aged animals compared to vehicle controls. GDF-8 recombinant protein is used in aged primary satellite cell cultures to test whether the elevated myostatin signaling in aging muscle is causally responsible for impaired regeneration, or whether the elevated GDF-8 is a marker of other age-related changes.
Yes. YourPeptideBrand.com provides white-label dropship for recombinant GDF-8 as YPB.233 (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with ActRIIB/Smad2/3 mechanism descriptions, research application context (atrophy induction, inhibitor validation, sarcopenia models), and COA library links. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue. For maximal catalog impact, offer GDF-8 (YPB.233) alongside ACE-031 (YPB.249) as the paired agonist/antagonist ActRIIB toolkit — the only such pair available in a white-label research catalog.
Every GDF-8 batch includes a lot-specific COA: HPLC purity (≥95%; SDS-PAGE purity for recombinant proteins), MS confirmation at expected molecular weight for the mature GDF-8 dimer, N-terminal sequence verification or intact protein MS to confirm GDF-8 vs. GDF-11 identity (critical given 90% sequence identity), bioactivity confirmation (Smad2/3 phosphorylation in myoblast cell-based assay at expected EC50), endotoxin (<1 EU/mg), and TAMC/TYMC. The bioactivity assay and identity confirmation by sequencing/intact MS are the most critical quality parameters for recombinant GDF-8 — purity alone does not confirm correct protein identity or biological activity. All lots are traceable through the batch-specific COA library.
GDF-8 and ACE-031 are the ActRIIB pathway agonist and antagonist — the two tools that define both endpoints of the myostatin signaling axis. Position them as companion research tools rather than competing products: “GDF-8 activates the myostatin pathway (induces Smad2/3 signaling); ACE-031 blocks it (removes myostatin and activins from the system). Together they enable the inhibitor-rescue design that is the gold standard for confirming ActRIIB-specific effects.” Researchers who need one will naturally need the other for complete experimental design: the “GDF-8 + ACE-031 rescue” experiment is standard practice in the field. For catalog content, GDF-8 serves the atrophy/disease mechanism researchers; ACE-031 serves the hypertrophy/therapeutic target researchers; both audiences are drawn from the same muscle biology buyer pool, and offering the pair positions the catalog as a comprehensive ActRIIB biology toolkit rather than individual compound listings.
Key Takeaways
Research Takeaways
- McPherron 1997 Nature (PMID: 9139826): Foundational discovery; GDF-8 KO mice = doubled muscle mass; established myostatin as the primary endogenous muscle mass negative regulator.
- Receptor cascade: ActRIIB → ALK4/5 → Smad2/3 → MuRF1/MAFbx + MyoD suppression + mTOR inhibition: Three convergent atrophy arms; each independently assayable; phospho-Smad2 at 30–60 min is the canonical acute endpoint.
- Recombinant active dimer bypasses propeptide regulation: Immediately receptor-competent; reconstitute in 0.1% BSA/PBS to prevent aggregation.
- ~90% GDF-11 sequence identity: N-terminal sequencing or intact MS required for identity confirmation; anti-GDF-8 antibody GDF-11 selectivity must be validated.
- GDF-8 + ACE-031 = canonical ActRIIB agonist/antagonist pair: Inhibitor-rescue design is the standard for confirming pathway-specific effects; neither compound provides complete experimental design without the other.
- Elevated in muscle wasting diseases: Sarcopenia, DMD, cancer cachexia, HIV wasting — positions GDF-8 research across multiple disease-focused funding streams.
Business Takeaways
- 8,000+ PubMed publications — one of the most extensively studied signaling proteins in muscle biology; established research audience.
- Only ActRIIB pathway agonist in YPB catalog — direct complement to ACE-031; neither is complete without the other for rigorous research design.
- GDF-8 + ACE-031 + IGF-1 LR3 muscle trio covers atrophic signaling (GDF-8), pathway inhibition (ACE-031), and anabolic counter-axis (IGF-1 LR3) — complete muscle mass regulation toolkit from a single buyer audience.
- Contact YPB for confirmed pricing on YPB.233.
Ready to add GDF-8 to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”gdf-8″]